Expression of the VP40 antigen from the Zaire ebolavirus in tobacco plants

Planta

Volumn 246, Issue 1, 2017, Pages 123-132

  Monreal Escalante, Elizabeth ^a   Ramos Vega, Abel A ^b   Salazar González, Jorge A ^a   Bañuelos Hernández, Bernardo ^a   Angulo, Carlos ^b   Rosales Mendoza, Sergio ^a  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Antigen delivery system; Ebola; Humoral response; Molecular pharming; Oral vaccine; Subunit vaccine

Indexed keywords

MATRIX PROTEIN; VIRUS ANTIBODY; VP40 PROTEIN, VIRUS;

ANIMAL; BAGG ALBINO MOUSE; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENE EXPRESSION; GENETICS; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MOUSE; TOBACCO; TRANSGENIC PLANT;

ANIMALS; ANTIBODIES, VIRAL; EBOLAVIRUS; GENE EXPRESSION; HEMORRHAGIC FEVER, EBOLA; IMMUNIZATION; MICE; MICE, INBRED BALB C; PLANTS, GENETICALLY MODIFIED; TOBACCO; VIRAL MATRIX PROTEINS;

EID: 85017150342     PISSN: 00320935     EISSN: 14322048     Source Type: Journal    
DOI: 10.1007/s00425-017-2689-5     Document Type: Article

References (42)

1. Becquart P, Mahlakõiv T, Nkoghe D, Leroy EM (2014) Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus. PLoS One 6:e96360. doi:10.1371/journal.pone.0096360
2. Benchabane M, Goulet C, Rivard D, Faye L, Gomord V, Michaud D (2008) Preventing unintended proteolysis in plant protein biofactories. Plant Biotechnol J 6:633–648
3. Bociaga-Jasik M, Piatek A, Garlicki A (2014) Ebola virus disease—pathogenesis, clinical presentation and management. Folia Med Cracov 54:49–55
4. Cangelosi GA, Best EA, Martinetti G, Nester EW (1991) Genetic analysis of Agrobacterium. Methods Enzymol 204:384–397
5. Chia MY, Hsiao SH, Chan HT, Do YY, Huang PL, Chang HW, Tsai YC, Lin CM, Pang VF, Jeng CR (2011) Evaluation of the immunogenicity of a transgenic tobacco plant expressing the recombinant fusion protein of GP5 of porcine reproductive and respiratory syndrome virus and B subunit of Escherichia coli heat-labile enterotoxin in pigs. Vet Immunol Immunopathol 140:215–225
6. Connell TD (2007) Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev Vaccines 6:821–834
7. De Martinis D, Rybicki EP, Fujiyama K, Franconi R, Benvenuto E (2016) Editorial: plant molecular farming: fast, scalable, cheap, sustainable. Front Plant Sci 7:1148
8. Dellaporta SL, Wood J, Hicks JB (1983) A plant DNA minipreparation: version II. Plant Mol Biol Rep 1:19–21
9. Feldmann H, Sanchez A, Geisbert TW (2006) Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams & Wilkins, Philadelphia, pp 1409–1448
10. Freed EO (2002) Viral late domains. J Virol 76:4679–4687
11. Govea-Alonso DO, Cardineau GQ, Rosales-Mendoza S (2014) Principles of plant-based vaccines. In: Rosales-Mendoza S (ed) Genetically engineered plants as a source of vaccines against wide spread diseases—an integrated view. Springer Science + Business Media, New York, pp 1–14. ISBN 978-1-4939-0850-9
12. Hernández M, Rosas G, Cervantes J, Fragoso G, Rosales-Mendoza S, Sciutto E (2014) Transgenic plants: a 5-year update on oral antipathogen vaccine development. Expert Rev Vaccines 12:1523–1536
13. Horsch RB, Fry JE, Hoffmann NL, Eichholtz D, Rogers SG, Fraley RT (1985) A simple and general method for transferring genes into plants. Science 227:1229–1231
14. Ingham DJ, Beer S, Money S, Hansen G (2001) Quantitative real-time PCR assay for determining transgene copy number in transformed plants. Biotechniques 31(132–134):136–140
15. Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y (2001) Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 75:5205–5214
16. Jefferson RA (1987) Assaying chimeric genes in plants: the GUS gene fusion system. Plant Mol Biol Rep 5:387–405
17. Kim SI, Veena JH, Gelvin SB (2007) Genome-wide analysis of Agrobacterium T-DNA integration sites in the Arabidopsis genome generated under non-selective conditions. Plant J 51:779–791
18. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchkov VE, Jahrling PB (2010) Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155:2083–2103
19. Leroy EM, Epelboin A, MondongeV Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ, Formenty P (2009) Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo. Vector Borne Zoonotic Dis 9:723–728
20. Loos A, Steinkellner H (2014) Plant glyco-biotechnology on the way to synthetic biology. Front Plant Sci 5:523
21. Lugade AA, Kalathil S, Heald JL, Thanavala Y (2010) Transgenic plant-based oral vaccines. Immunol Invest 39:468–482
22. Marsh GA, Haining J, Robinson R, Foord A, Yamada M, Barr JA (2011) Ebola Reston virus Infection of pigs: clinical significance and transmission potential. J Infect Dis 204:S804–S809
23. McCarthy M (2014) US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 349:g5488
24. Monreal-Escalante E, Govea-Alonso DO, Hernández M, Cervantes J, Salazar-González JA, Romero-Maldonado A, Rosas G, Garate T, Fragoso G, Sciutto E, Rosales-Mendoza S (2016) Towards the development of an oral vaccine against porcine cysticercosis: expression of the protective HP6/TSOL18 antigen in transgenic carrots cells. Planta 3:675–685
25. Nawar HF, Arce S, Russell MW, Connell TD (2005) Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside binding activities. Infect Immun 73:1330–1342
26. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y (2002) Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 76:4855–4865
27. Noda T, Hagiwara K, Sagara H, Kawaoka Y (2010) Characterization of the Ebola virus nucleoprotein–RNA complex. J Gen Virol 91:1478–1483
28. Phoolcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, Mason HS (2011) Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnol J 9:807–816
29. Pillet S, Aubin É, Trépanier S, Bussière D, Dargis M, Poulin JF, Yassine-Diab B, Ward BJ, Landry NA (2016) Plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol 168:72–87
30. Pniewski T, Kapusta J, Bociąg P, Wojciechowicz J, Kostrzak A, Gdula M, Fedorowicz-Strońska O, Wójcik P, Otta H, Samardakiewicz S, Wolko B, Płucienniczak A (2011) Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation. J Appl Genet 52:125–136
31. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB et al (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53
32. Rosales-Mendoza S, Salazar-González JA (2014) Immunological aspects of using plant cells as delivery vehicles for oral vaccines. Expert Rev Vaccines 13:737–749
33. Salazar-Gonzalez JA, Rosales-Mendoza S, Romero-Maldonado A, Monreal-Escalante E, Uresti-Rivera EE, Bañuelos-Hernández B (2014) Production of a plant-derived immunogenic protein targeting ApoB100 and CETP: toward a plant-based atherosclerosis vaccine. Mol Biotechnol 56:1133–1142
34. Sun Y, Carrion R Jr, Ye L, Wen Z, Ro YT, Brasky K, Ticer AE, Schwegler EE, Patterson JL, Compans RW, Yang C (2009) Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 383:12–21
35. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S (2005) Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23:3033–3042
36. Tacket CO (2009) Plant-based oral vaccines: results of human trials. Curr Topics Microbiol Immunol 332:103–117
37. Takeyama N, Kiyono H, Yuki Y (2015) Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Ther Adv Vaccines 3:139–154
38. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S (2003) Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 100:15889–15894
39. + T cell responses are required for protection against lethal Ebola virus infection. J Immunol 175:1184–1191
40. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2:430–437
41. WHO (2014) Ebola virus disease. http://www.who.int/mediacentre/factsheets/fs103/en Accessed 23 June 2016
42. WHO (2015) Ebola situation report. http://apps.who.int/ebola/ebola-situation-reports Accessed 23 June 2016